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To investigate the effects of CCL21/CCR7 on the proliferation, migration, and invasion of
T24 cells and the possible associated mechanisms: expression of MMP-2 and MMP-9, and
regulation of BCL-2 and BAX proteins.

Methods
T24 cells received corresponding treatments including vehicle control, antibody (20ng/mL
CCR7 antibody and 50 ng/ml CCL21), and 50, 100, and 200 ng/ml CCL21. Proliferation was
evaluated by MTT assay; cell migration and invasion were assayed using a transwell chamber. Cell apoptosis was induced by Adriamycin (ADM). The rate of cell apoptosis was examined by flow cytometry using annexin V-FITC/PI staining. Western-blot was used to analyze
MMP-2 and MMP-9 and BCL-2 and BAX proteins.

Results
CCL21 promoted T24 cell proliferation in concentration-dependent manner with that
200 ng/mL induced the largest amount of proliferation. Significant differences of cell
migration were found between CCL21treatment groups and the control group in both the
migration and invasion studies (P < 0.001 for all). The expressions of MMP-2 and MMP-9
proteins were significantly increased after CCL21 treatment (p < 0.05 for all). Protein expression of Bcl-21 follows an ascending trend while the expression of Bax follows a descending trend as the concentration of CCL21 increases. No difference was found between
the control group and antibody group for all assessments.
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Conclusion
CCL21/CCR7 promoted T24 cell proliferation and enhanced its migration and invasion via
the increased expression of MMP-2 and MMP-9. CCL21/CCR7 had antiapoptotic activities
on T24 cells via regulation of Bcl-2 and Bax proteins. CCL21/CCR7 may promote bladder
cancer development and metastasis.

Introduction
Bladder cancer is one of the most common types of adult cancer. In 2008 alone, 386,000 patients were diagnosed with bladder cancer which resulted in 150,200 deaths worldwide based
on global statistics[1]. Metastasis is not only a hallmark of bladder cancer, but also the cause of
mortality[1]. However, the pathophysiology of bladder cancer metastasis remains unclear.
Chemokines, a superfamily of small secreted peptides characterized by their ability to induce
leukocyte migration, together with their receptors have been found to be involved in the migration of cells of the lymphoid system, thus may affect cancer development and progression[2–
4]. CCL21, an important chemokine of the CCL family, is one of the only two ligands (the
other one is CCL19) for CCR7.[5] CCL21 is produced by fibroblastic reticular cells of the Tcell rich area in human and high endothelial venules in mice. [6] CCR7 is expressed by various
types of lymphocytes including naive B and T cells, semimature and mature dendritic cells, and
T regulatory cells[5]. In addition, the expression of CCR7 has been reported to promote cancer
cell metastasis to lymph nodes in nonsmall cell lung cancer[7], breast cancer[8], squamous cell
carcinoma of head and neck cancer [9], colorectal cancer[10], prostate cancer [11], esophageal
squamous cell cancer[12] and gastric cancer[13]. Therefore, CCR7 and its ligand (s) may participate in the proliferation, progression, and metastasis of cancer cells of various organ origins
[7–13]. We also found that CCR7 was involved in the development and progression of bladder
cancer (unpublished data).
Physiologically, CCL21/CCR7 plays important roles in homing of immune cells, lymphnode homing and positioning, immunity and peripheral tolerance, development and function
of T regulatory cells, and autoimmunity and lymphoid neogensis[5]. Various studies have confirmed the roles of CCL21/CCR7 in tumor development and progression[14–17]. For example,
CCL21/CCR7 promotes G2/M phase progression and prevents apoptosis via the ERK pathway
in human non-small cell lung cancer[15, 16], facilitates the progression of pancreatic cancer
via induction of angiogenesis and lymphangiogenesis[14], regulates matrix metalloproteinase9 (MMP-9) in human colon cancer metastasis[18], and upregulates MMP-9 in B-cell chronic
lymphocytic leukemia cell migration and invasion [17]. Furthermore, CCL21/CCR7 was also
found to promote cancer cell migration into microlymphatic vessels in breast cancer[19], pancreatic tumor[20], lung adenocarcinoma [21], and esophageal squamous cell carcinoma[22].
However, the possible role of CCL21/CCR7 in bladder cancer development and progression remains unclear. T24 cells are derived from transitional cell carcinoma of human urinary bladder
and have been extensively utilized for the study of bladder cancer[23].
The purposes of the present study were to investigate the effects of CCL21/CCR7 on the
proliferation, migration, and invasion of T24 cells and the possible associated mechanisms: expression of MMP-2 and MMP-9, and regulation of BCL-2 and BAX proteins.
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Materials and Methods
This study obtained ethics approval from the ethics committee at Xiangya Hospital, Central
South University, Changsha, Hunan Province, China.

Reagents and cell line
CCL21 recombinant human protein was purchased from Perprotech (Rocky Hill, NJ, USA)
and polyclonal rabbit anti-human CCR7 antibody was purchased from Wuhan Boster Biological Engineering Co., Ltd. (Wuhan, China). Protease inhibitor Phenylmethylsulfonyl fluoride
(PMSF) was purchased from Roche Diagnostics (Indianapolis, IN, USA). MTT and Dimethyl
sulfoxide (DMSO) was purchased from Hufeng Chemical Co., Ltd. (Shanghai, China).
Annexin V-FITC apoptosis detection kit was purchased from Beyotime Biotechnology (Shanghai, China).
The human bladder cancer T24 cell line was purchased from the Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences (Shanghai, China). The cells were cultured
at 37°C, 5% CO2, in medium of DMEM (GIBCO, USA) containing 10% fetal bovine serum,
100 U/mL penicillin, and 100 U/mL streptomycin.

Cell culture and treatment
T24 cells were treated for 48 hours prior to MTT assay, migration and invasion assays, and
Western blot analysis and 24 hours prior to flow cytometry study. For each experiment, there
were five groups consisting of Group 1 (control group) which was treated with serum free
DMEM medium, Group 2 (antibody group) which first received pretreatment of 20 ng/mL of
polyclonal rabbit anti-human CCR7 antibody for 4 h then 50 ng/ml of CCL21, Group 3 which
received 50 ng/ml of CCL21, Group 4 which received 100 ng/ml of CCL21, and Group 5 which
received 200 ng/ml of CCL21. The experiments of MTT assay, flow cytometry, and Western
blot were repeated three times (n = 3), and cell migration and invasion were repeated four
times (n = 4).

MTT assay for the proliferation of T24 cells
Proliferation of T24 cells was evaluated by MTT assay. In brief, cells were treated correspondingly in each group for 48 hours. Following treatment, the medium was removed and the cells
were incubated with 5mg/mL of MTT solution (20μl). After incubation for 4 h at 37°C and 5%
CO2, the supernatant was removed and formation of formazan was measured at 490 nm with
Gel Documentation & Analysis System set (Liuyi Factory, Beijing, China).

Migration and invasion assays
Cell migration and invasion were assayed using a transwell chamber (EMD, Millipore, USA).
For the invasion assay, a transwell chamber was placed into a 24-well plate and was coated
with 30 μl Matrigel (Franklin Lakes, USA) and was incubated for one hour at 37°C. In both
transwell assays, cells, after 48 hours' corresponding treatment, were trypsinized and seeded in
chambers at the density of 8 × 104 cells per well, and 500 μl of serum free DMEM medium was
added to the lower chamber. Migrated cells were fixed with 100% Matrigel (BD, Franklin
Lakes, USA) methanol for 30 min after 24 hours, and non-migrated Cells were removed by cotton swabs. Finally, cells on the bottom surface of the membrane were stained with hematoxylin
and eosin for 20 min. Optical microscope (200X, Olympus, Tokyo, Japan) was used to count
the number of cells in five random fields of view; mean cell number was calculated for each
group.
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Flow cytometry for apoptosis
Cell apoptosis was induced by Adiamycin (ADM). The rate of apoptosis of T24 cells was examined by flow cytometry using annexin V-FITC/PI staining. Briefly, T24 cells were treated as
above in each group for 24 h; cells were then incubated with ADM (0.1mg/ml) for additional
48 h. Then cells were harvested, washed and resuspended in PBS. Apoptotic cell death was
measured by double staining annexin V-FITC and PI using the annexin V-FITC apoptosis detection kit (Beyotime Biotechnology, Shanghai, China) as per the manufacturer’s instructions.
Flow cytometric analysis was performed immediately after staining. Data acquisition and analysis were performed by flow cytometry using the Cell Quest software.

Western blot analysis
T24 cells were placed into 75 mL culture vials and were incubated at 37°C for 24 h and then
treated correspondingly in each group for 48h incubation. Suspensions were washed with cold
PBS. The cells were then incubated in ice-cold RIPA buffer [1 M Tris (pH 7.4), 5 M NaCl,
0.5 M EDTA (pH 8.0), 10% SDS, 10% DOS, and 10% NP40] with fresh protease inhibitor
PMSF over ice for 20 min. The cells were scraped and the lysate was collected in an Eppendorff
tube and centrifugated at 10,000 rpm at 4°C for 10 min, and the supernatants were collected,
aliquoted, and stored at -20°C for future use.
Dilutions of BCL-2/BAX (12%) and MMP-2/MMP-9 (7.5%) were used for the study. Proteins
(20 μg) were loaded in 5–15% SDS-PAGE gels and transferred onto a nitrocellulose membrane
(Amersham Biosciences, USA). The membranes were soaked in blocking buffer (5% skimmed
milk) under room temperature for 2 h. The blots were washed with PBS (with 0.1% BSA). To
probe for MMP-2, MMP-9, BCL-2, Bax, and β-actin, the membranes were incubated 2h under
room temperature with relevant antibodies, followed by appropriate HRP conjugated secondary
antibodies and ECL detection. Gel Documentation & Analysis System set (Liuyi Factory, Beijing,
China) was used for picture capture and analysis of Optical density (OD) values (490nm).

Statistical analysis
Statistical analysis was performed using the SPSS 18.0 statistical software. Quantitative data
were expressed as the mean ± SD. One-way analysis of variance with Fishers LSD test was used
for group comparisons. The significance level was set at p-value less than 0.05.

Results
Effects of CCL21/CCR7 on the proliferation of T24 cells
The effects of CCL21/CCR7 on T24 cells as represented by OD values are presented in Table 1.
OD values were 0.211 ± 0.013 in the control group, 0.216 ± 0.011 in the antibody group
Table 1. Effect of CCL21 on T24 cell proliferation.
Groups

OD value

P-values

Control (DMEM medium)

0.211 ± 0.013

—

Anti-CCR7 Ab + CCL21 50 ng/mL

0.216 ± 0.011

P > 0.05

50ng/mL Group

0.248 ± 0.006

P < 0.05

CCL21 100 ng/mL

0.290 ± 0.004

P < 0.01

CCL21 200 ng/mL

0.341 ± 0.012

P < 0.001

Note: The OD values present Mean ± SD from 3 independent experiments.
doi:10.1371/journal.pone.0119506.t001
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Fig 1. Effect of CCL21 with or without CCR7 antibody on cell migration and invasion of T24 cells. The assay was performed using a transwell chamber
coated with 30 μl of Matrigel mixture solution with five different groups consisting of vehicle control, CCR7 antibody 20 ng/ml plus CCL21 50 ng/ml, CCL21
50 ng/ml, CCL21 100 ng/ml, and CCL21 200 ng/ml. The data present Mean ± SD from four independent experiments.
doi:10.1371/journal.pone.0119506.g001

(p>0.05 as compared with control), 0.248 ± 0.006 in 50 ng/ml of CCRL21 (P < 0.05 as compared with control), 0.290 ± 0.004 for 100 ng/ml of CCRL21 (P < 0.01 as compared with control), and 0.341 ± 0.012 for 200 ng/mL of CCRL21 (P < 0.001 as compared with control).
CCL21 promoted T24 cell proliferation in concentration-dependent manner with 200 ng/mL
induced the largest amount of proliferation.

Effects of CCL21/CCR7 on the migration and invasion of T24 cells
The results of CCL21/CCR7 on the migration and invasion of T24 cells are presented in Fig. 1.
Cell counts for the migration and invasion studies are as the following: 45.5±11.6 and 28.6±
15.0 for the control group, 42.5±13.6 and 30.5±15.2 for the antibody group, 72.9±22.4 and
55.5±13.6 for CCRL21 100 ng/mL group, 115.7±18.8 and 102.1±18.0 for CCRL21 150 ng/mL
group, and 178.9±8.4 and 143.7±24.4 for CCRL21 200 ng/mL group. Significant differences of
cell migration were found between either of the three CCL21treatment groups and the control
group in both the migration and invasion studies (P < 0.001 for all); but, no difference was
found between the control group and the antibody group in either the migration study or the
invasion study (P > 0.05 for both). The effect of CCL21/CCR7 treatment on T24 cell migration
is concentration-dependent with the highest concentration of CCL21 (200 ng/ml) produced
the largest number of cells of migration/invasion. In general, smaller numbers of T24 cells were
found in the invasion study than that of the corresponding migration study.
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Fig 2. Effects of CCL21 with or without CCR7 antibody on the expression of MMP-2, MMP-9, Bcl-2,
Bax, VEGF-C, and HuR by Western blot analysis. Lane 1: T24 cells treated with vehicle control; Lane 2:
T24 cells treated with CCR7 antibody 20 ng/ml plus CCL21 50 ng/ml; Lane 3: T24 cells treated with 50 ng/ml
CCL21; Lane 4: T24 cells treated with 100 ng/ml CCL21; and Lane 5: T24 cells treated with 200 ng/ml
CCL21. Cell lysates were prepared and run on 5–15% SDS-PAGE gels following by a Western blot analysis.
Beta-actin was used as a loading control. The blots shown are representative of three independent
experiments.
doi:10.1371/journal.pone.0119506.g002

Effects of CCL21/CCR7 on the expression of MMP-2 and MMP-9 in T24
cells
Western blot results are presented in Fig. 2; quantitative measurements of MMP-2 and MMP-9
are presented in Table 2. Significant differences were found in the expression of MMP-2 and
MMP-9 among the five groups (p < 0.05). As compared to the control group, the expressions
of MMP-2 and MMP-9 proteins were significantly increased after three different concentrations of CCL21 treatment (p < 0.05 for all). However, no difference was found in MMP-2 or
MMP-9 between the control group and the antibody group (p > 0.05 for both).

Effects of CCL21/CCR7 on apoptosis in T24 cells
Effects of CCL21/CCR7 on the expressions of Bcl-2 and Bax by Western blot are presented in
Fig. 2 and the OD values are presented in Fig. 3. Protein expression of Bcl-21 follows an ascending trend while the expression of Bax follows a descending trend as the concentration of
CCL21 increases. Significant differences were found in the expressions of Bcl-2 and Bax between CCL21 50 ng/ml group and CCL21 100 ng/ml group (p<0.05 for both) and between
CCL21 50 ng/ml group and CCL21 200 ng/ml (p<0.05 for both) but not between CCL21
100 ng/ml group and CCL21 200ng/ml (p = 0.545 for Bcl-2 and p = 0.191 for Bax). Again, no
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Table 2. Effects of CCL21/CCR7 on MMP-2 and MMP-9 expression as represented via OD values.
Groups

MMP-2

MMP-9

Control

0.26 ± 0.03

0.17 ± 0.04

Anti-CCR7 Ab + CCL21 50 ng/ml

0.32 ± 0.05

0.20 ± 0.06

CCL21 50 ng/ml

0.43 ± 0.05

0.33 ± 0.05

CCL21 100 ng/ml

0.67 ± 0.07

0.41 ± 0.06

CCL21 200 ng/ml

0.80 ± 0.10

0.65 ± 0.08

Note: The OD values present Mean ± SD from 3 independent experiments.
doi:10.1371/journal.pone.0119506.t002

difference was found between the control group and the antibody group for either Bcl-2 or Bax
(p>0.05 for both).
Early and late apoptosis rates and total cell death rates after treatments are presented in
Table 3. The rates of early apoptosis, late apoptosis and total cell death rates in the control
group are 26.4 ± 5.0%, 37.5 ± 2.4%, and 63.9 ± 7.1%, respectively; whereas in the antibody
group are 25.2 ± 3.8%, 35.6 ± 5.5%, and 60.8 ± 9.3%, respectively. No difference in apoptosis
rates was found in each stage between the two groups (p > 0.05 for all). The rates of early apoptosis, late apoptosis and total cell death dropped after CCL21 treatments at 50, 100, and
200 ng/ml. Compared with control group, significant decreases in total cell apoptosis were
found in CCL21 treatment groups (p < 0.001 for all three treatment groups); however, no significant difference was found among the three CCL21 treatment groups in total cell apoptosis
(p > 0.05 for all). Compared with control group, significant decreases were also found in early
cell apoptosis in CCL21 treatment groups (p = 0.008 for 200 ng/mL, 0.001 for 100 ng/mL, and
0.027 for 50 ng/mL); however, again, no significant difference was found among the three
CCL21 treatment groups in early apoptosis (p > 0.05 for all).

Fig 3. Effects of CCL21 with or without CCR7 antibody on the expressions of Bcl-2 and Bax. T24 cells were treated with vehicle control, CCR7 antibody
20 ng/ml plus CCL21 50 ng/ml, CCL21 50 ng/ml, CCL21 100 ng/ml, and CCL21 200 ng/ml. The values (OD) present Mean ± SD from three
independent experiments.
doi:10.1371/journal.pone.0119506.g003
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Table 3. Antiapoptotic effects of CCL21/CCR7 on T24.
Groups

Early apoptosis
(%)

Late apoptosis/
necrosis (%)

Total cell death (%)

Control

26.4 ± 5.0

37.5 ± 2.4

63.9 ± 7.1

Anti-CCR7 Ab 50 ng/ml + CCL21 50 ng/ml

25.2 ± 3.8

35.6 ± 5.5

60.8 ± 9.3

CCL21 50 ng/ml

19.6 ± 2.7

16.5 ± 2.1

36.1 ± 1.0

CCL21 100 ng/ml

14.9 ± 1.8

17.8 ± 1.4

32.7 ± 1.5

CCL21 200 ng/ml

17.7 ± 1.4

16.4 ± 3.3

34.1 ± 2.4

Note: The values present Mean ± SD from 3 independent experiments.
doi:10.1371/journal.pone.0119506.t003

Discussion
The potential of cancer cells to metastasize depends on its interactions with homeostatic factors
including chemokines which not only promote cancer cell growth and survival but also migration and invasion or metastasis. Previous studies have demonstrated that chemokines are involved in the progression and metastasis of various cancers[2, 4, 5]. CCR7 is involved in cancer
metastasis to lymph nodes in various cancers[7–13]. CCL21 participates in the proliferation of
CD4 T cells, kidney mesangial cells, and various cancer cells[19, 24–27]. Our study demonstrated for the first that CCL21/CCR7 could increase T24 cell proliferation (Table 1), migration
and invasion (Fig. 1).
Chemokine concentration may be at least in part responsible for cancer development and
metastasis[19, 26]. As a result, we used three different concentrations of CCL21 in the present
study and found a concentration dependent manner in CCL21 effects on T24 cell proliferation,
migration, and invasion. CCL21 may strongly increase T24 cell migration and invasion at high
concentrations and thus facilitate bladder cancer metastasis. Our findings are consistent with
these previous reports.
The interaction of chemokines and their receptors serve as the foundation for tumor cell
motility and migration via triggering intracellular actin polymerization to create pseudopodia
[28, 29]. Muller et al found that CCL21 at100 nM induced a transient 1.6-fold increase in intracellular flamentous actin (F-actin) in human breast cancer cells within 20 seconds and observed distinct pseudopodia formation after 20 min of stimulation with CCL21[19]. The results
of present study with T24 cell migration and invasion are consistent0020with these previous
reports. Significant decrease in T24 cell numbers was observed when CCR7 antibody was used
together with CCL21 and it indicates that effect of CCL21 depends on the activity of CCR7.
On the other word, CCL21 may activate CCR7 first and then affect T24 cell migration and
invasion.
Molecules like chemokine CCL21 are involved in the metastasis of cancers not only via mediating the migration and invasion of cancer cells into tissues but also providing the required
supportive microenvironments. In vivo, the migration of cancer cells is often slowed with lots
of resistances, such as basement membrane and surrounding connective tissue[29, 30]. Therefore, to mimic the real in vivo condition, we utilized transwell chamber coated with matrigel as
a physical barrier for the present study. MMP-2 and MMP-9 are two proteins which are closely
associated with bladder cancer metastasis[31–33]. Cancer cell invasion may require the secretion of MMPs such as MMP-2 and MMP-9 to degrade the matrigel. In the present study, we
found that CCL21 could increase the expression of MMP-2 and MMP-9 and thus enhance cell
invasion (Fig. 2 and Table 2). MMPs play important roles in cancer cell invasion; but other factors such as interleukins and E-cadherin may also contribute to tumor progression and
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invasion [34–37]. Nonetheless, CCL21/CCR7 may facilitate cancer cell invasion via increasing
MMP secretion and enhancing cell motility.
Using radiolabled techniques, researchers have found only a tiny portion of radiolabled cancer cells in microcirculations has the potential to metastasize[38]. The survival of cancer cells
depends on their antiapoptotic abilities. When tumor cells leave its original tissues, they will
lose some if not all the homeostatic factors which include chemokines for adhesion and support; thus the cells are prone to apoptosis. In the present study, the antiapoptotic ability of
CCL21 inT24 cells were investigated using flow cytometry by annexin V-FITC/PI staining via
ADM induced apoptosis. Phosphatidylserine (PS) can specifically bind annexin-V. PI, a nuclear staining agent, cannot cross normal cell membrane. In the early phase of apoptosis, PI nuclear staining cannot be detected as the cell membrane is intact. However, as cell undergoes
apoptosis in the middle to late phases, cell membrane blebs and is no longer intact; thus nucleus can be detected through PI staining.
The result of the flow cytometry can be divided into four quadrants: the lower left quadrant
with normal alive cells [Annexin-V (−), PI (−)], the upper right quadrant [Annexin-V (+), PI
(+)] with late apoptotic or necrotic cells, the lower right quadrant [Annexin-V (+), PI (−)] with
early apoptotic cells, and the upper left quadrant [Annexin-V (−), PI (+)] with small portions
of cell debris due to mechanical injury and apoptosis. Thus, the analysis of apoptosis mainly
depends on early apoptosis (lower right quadrant) and total cell death (upper right + lower
right quadrants) in the present study. Our results demonstrated significant decrease of apoptosis and cell death with CCL21 treatment compared to the control (p < 0.01); however, no difference between CCR7 antibody plus CCL21 treatment and the control was found (p > 0.05).
The results indicate that CCR7 antibody could antagonize the effect of CCL21 on apoptosis
and cell death and thus confirm the antiapoptotic function of CCL21/CCR7. However, no difference of apoptosis was detected among the three treatment groups (p > 0.05). The possible
cause could be that CCL21 at 50 ng/mL reached saturate condition thus higher concentrations
could not further increase it effect.
Bcl-2 family is found to be closely related to cell apoptosis[39–41]. Bcl-2 and Bax are the
two most important proteins in the Bcl-2 family with Bcl-2 inhibiting apoptosis while Bax promoting apoptosis. These two proteins are present in dimers, such as Bcl-2/Bcl-2 and Bax/Bax.
Upregulation of Bcl-2 expression will lead to the additional Bcl-2 to combine with Bax forming
Bcl2/Bax thus inhibit cell apoptosis; whereas with downregulation of the expression of Bcl-2,
the quantity of the combined form of Bcl2/Bax will decrease and thus promote cell apoptosis.
In the present study, we investigated the expression of Bcl-2 and Bax proteins in T24 cells in all
experimental groups including the control. CCL21 could increase Bcl-2 protein expression but
decrease Bax protein expression and the effects exhibited a CCL21 concentration dependent
manner between 50 ng/mL and 100 ng/ml. Interestingly, no significant difference was found in
Bcl-2 and Bax expressions between CCL21 at 100 ng/mL and 200 ng/ml CCL21 (Bcl-2:
p = 0.545; Bax: p = 0.191); the cause may be that CCL21 reached to a certain concentration no
higher than 100 ng/mL for its maximal anti-apoptotic effects (Fig. 3). Pretreatment of CCR7
antibody could almost completely reverse the effect of CCL21 on the expressions of Bcl-2 and
Bax and apoptosis (Fig. 3 and Table 3). This further confirms the vital role of CCR7 on the effects of CCL21 on T24 cells.

Conclusion
CCL21/CCR7 promoted T24 cell proliferation in a concentration dependent pattern and enhanced its migration and invasion; these effects may be related to the increased expression of
MMP-2 and MMP-9. CCL21/CCR7 had antiapoptotic activities on T24 cells; these functions
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may be related to the regulation of Bcl-2 and Bax proteins. Our results indicate that CCL21/
CCR7 may promote bladder cancer development and metastasis.
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